Blog Header

The Blog

29 Apr, 2019Bispecific Antibodies: Emerging Novel Immunotherapies for Cancer


Therapeutic antibody drugs have recently experienced explosive growth due in large part to the fact that immunotherapies stimulate the immune system to attack cancer cells. Within oncology research alone, more than 20 therapeutic antibody drugs received FDA approval for new treatments or indications during 2015 to 2018. Additionally, more than 300 therapeutic antibody drugs are in ongoing clinical trials.

Read More

02 Apr, 2019Tissue Processing in the 21st Century

How can I incorporate innovative techniques to make my histology workflow easier and more reliable?

Breathtaking progress in life sciences has brought us innovations such as high-throughput and individually affordable genomic sequencing as well as next-generation flow cytometry that can phenotype dissociated cells for their expression of dozens of markers simultaneously.

Read More

13 Mar, 2019An Overview of Outsourcing in the Life Sciences, Part II:
Why Outsource?


In part I we examined the evolution of outsourcing in drug discovery. In part II we will examine with deeper focus the specific reasons why it is beneficial to outsource scientific experiments. Research organizations and even individual researchers outsource for a variety of reasons, but here are just a few.

Read More

27 Feb, 2019An Overview of Outsourcing in the Life Sciences, Part I: Seas of Change


 A recent white paper was released that traces the trajectory over the last ten years of 120 independent for-profit startups in the field of research workflows and scholarly communication. The author, Yvonne Campfens, presented the report at the Academic Publishing in Europe (APE) Conference held January 15-16, 2019 in Berlin.

Read More

18 Feb, 2019Trusted Human Sample Discovery Through the UKCRC TDCC


There are hundreds of thousands of human samples currently stored in the UK; the research questions they could address are endless. It has been well documented that human samples are excellent experimental models; their use early in drug development can decrease the risk of failed progression into Phase I and II trials.  

Read More